2021-000898-83: Phase II placebo controlled study, to evaluate the efficacy and safety of begelomab in combination with standard immunosuppressive therapy and/or corticosteroids in the treatment of patients with dermatomyositis Studio di fase II controllato con placebo per valutare l'efficacia e la sicurezza di begelomab in combinazione con una terapia immunosoppressiva standard e/o corticosteroidi nel trattamento di pazienti con dermatomiosite |
|
|
| Not yet recruiting | 2 | 20 | Europe | Begelomab, [Not applicable], Concentrate for solution for injection/infusion | ADIENNE SA | Dermatomyositis Dermatomiosite, Multisystem disorder with a variety of clinical manifestations (lung, joint, esophageal and cardiac); however, its features are the characteristic skin manifestations and muscle weakness. Disturbo multisistemico con una varietà di manifestazioni cliniche (polmonari, articolari, esofagee e cardiache); tuttavia, i segni principali sono manifestazioni cutanee e debolezza muscolare., Diseases [C] - Immune System Diseases [C20] | | | | |
2017-002715-34: A Phase I/II, open label, dose escalation study to investigate the pharmacokinetics, pharmacodynamics, safety and clinical activity of begelomab as an initial treatment of acute Graft-versus-Host Disease in combination with standard steroid therapy |
|
|
| Ongoing | 1/2 | 50 | Europe | BEGEDINA 2.0 mg/ml concentrate for solution for infusion, Concentrate for solution for infusion | ADIENNE SA, ADIENNE SA | Acute graft versus host disease after allogeneic hematopoietic stem cell transplantation or donor lymphocyte infusion, Acute Graft versus Host Disease, Body processes [G] - Immune system processes [G12] | | | | |
